#ASCO21: Nanobiotix says early data show 'very strong' signal that its nanoparticles can dial up antitumor response
While cancer immunotherapies have shown promise, Nanobiotix thinks it can use nanoparticles to dial up the tumor killing effect of radiation and checkpoint inhibitors. And just ahead of #ASCO21, the company said about 77% of patients who used the tech in a small Phase I trial saw their tumors shrink.
NBTXR3 consists of crystalline nanoparticles that are delivered by intratumoral injections. When activated by radiation, the nanoparticles absorb energy and deliver a “high quantity of damage,” CEO Laurent Levy told Endpoints News. It’s also designed to trigger an adaptive immune response and long-term anti-cancer memory.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.